Intellia Therapeutics (NTLA) Income from Continuing Operations (2015 - 2026)
Intellia Therapeutics' (NTLA) quarterly Income from Continuing Operations came in at 192166000.0 in Q1 2026, up 24.62% year-on-year from 154200361.59 in Q1 2025, and down 108.23% on a QoQ basis from 92284000.0 in Q4 2025.
Intellia Therapeutics (NTLA) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 12 years of Income from Continuing Operations data on file, last reported at 192166000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 24.62% year-over-year to 192166000.0 in Q1 2026; TTM through Mar 2026 was 625095000.0, a 6.39% increase from a year earlier, with the FY2025 full-year figure at 1326436000.0, down 4.47% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 192166000.0, down from 92284000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for NTLA reached as high as 92284000.0 in Q4 2025 and fell as low as 348575000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 174842294.12 across 5 years, with a median of 159358000.0 in 2023.
- Across the five-year window, Income from Continuing Operations soared 80.49% in 2022 and sank 97.63% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 108556000.0 in 2022, then plunged by 50.48% to 163355000.0 in 2023, then advanced by 22.56% to 126494000.0 in 2024, then gained by 27.04% to 92284000.0 in 2025, then sank by 108.23% to 192166000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 192166000.0 in Q1 2026, 92284000.0 in Q4 2025, and 222414000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Intellia Therapeutics | 1.32 Bn | 1.32 Bn | - | -192.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -192.17 Mn |
| Dec 31, 2025 | -92.28 Mn |
| Sep 30, 2025 | -222.41 Mn |
| Jun 30, 2025 | -118.23 Mn |
| Mar 31, 2025 | -254.93 Mn |
| Dec 31, 2024 | -126.49 Mn |
| Sep 30, 2024 | -143.90 Mn |
| Jun 30, 2024 | -142.44 Mn |
| Mar 31, 2024 | -128.99 Mn |
| Dec 31, 2023 | -163.36 Mn |
| Sep 30, 2023 | -158.19 Mn |
| Jun 30, 2023 | -188.32 Mn |
| Mar 31, 2023 | -159.36 Mn |
| Dec 31, 2022 | -108.56 Mn |
| Sep 30, 2022 | -220.59 Mn |
| Jun 30, 2022 | -203.53 Mn |
| Mar 31, 2022 | -348.58 Mn |
| Dec 31, 2021 | -82.04 Mn |
| Sep 30, 2021 | -673.57 Mn |
| Jun 30, 2021 | -1.04 Bn |